Developer docs
API playgroundTry for free, no card

Search company profiles

2A Pharma

Full company profile

uuid000qxwd

Namestring
2A Pharma
Legal namestring
2A Pharma ApS
Websiteurl
2apharma.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

2A Pharma AB is a clinical-stage Swedish/Danish biopharmaceutical company founded on December 12, 2016, developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform. The company operates from Malmö, Sweden (parent 2A Pharma AB, registration 559090-2788) and Aalborg, Denmark (operating entity 2A Pharma ApS, CVR 3939 1597) with 1-10 employees, and holds worldwide exclusive rights to the AAVLP technology in-licensed from Medigene AG in 2016. The AAVLP platform uses non-infectious protein scaffolds derived from AAV2 that mimic virus structure without containing viral genomic material, with two immunogenic capsid positions (453 and 587) enabling monovalent and bivalent vaccine design, B-cell receptor cross-linking, conversion of low-immunogenic peptides into immunogenic antigens, and pre-existing Th-cell immune response boosting from population-wide AAV2 seropositivity.

The company's lead candidate is 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine that completed a UK MHRA-approved Phase 1 clinical trial in 2020 and is positioned as the only L2-based HPV vaccine in clinical testing, claiming broader coverage than approved vaccines across alpha and beta HPV types. Its second disclosed asset, 2AP07 (AAVLP-EpCAM+), is a pre-clinical therapeutic vaccine for EpCAM+ cancers including head and neck, breast, colon, pancreatic and prostate cancers, developed in partnership with Danish Technological Institute and DNASense and supported by a EUR 653,000 Eurostars grant. The company also references pan-coronavirus and pan-Ebola vaccine collaborations with the Galveston National Laboratory and Stony Brook University, and exploratory autoimmune-disease work (vitiligo).

2A Pharma is pre-revenue and is monetizing the platform through future licensing, co-development, and outright commercialization pathways rather than current product sales. Revenue is expected upon regulatory approval and commercialization, with the option of licensing or partnership upfront payments in the interim. The company has raised cumulative seed funding of approximately EUR 7.9m from family offices (SEK 27m in 2016, USD 3m in 2018, plus additional capital through 2021) and is currently seeking Series A investment of EUR 15-20m to fund Phase 2 studies and IND progression, with plans for a Series B or IPO targeted for 2024. Customer-facing end markets in scope span patients at risk of HPV-related cancers (target market approximately USD 5.6 billion by 2023), EpCAM+ cancer patients (head and neck cancer market ~USD 1.3 billion, breast cancer drugs market projected to grow from USD 15.4 billion in 2020 to USD 31.1 billion in 2028), and autoimmune disease populations.

Short descriptiontext

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing prophylactic and therapeutic vaccines based on its proprietary AAVLP virus-like particle platform, targeting HPV-related cancers, EpCAM+ cancers, and selected infectious and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMalmö, Sweden
HQ citystring
Malmö
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, biopharmaceutical research, HPV cancer vaccines, virus-like particles, immunotherapy platform
Industry2 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Vaccines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company developing prophylactic and therapeutic vaccines. Currently in Phase 1 trials for HPV vaccine (2AP01). Seeking Series A investment of EUR 15-20m for Phase 2 studies and IND-ready progression. Revenue expected upon regulatory approval and commercialization of vaccine candidates.

2apharma.com
2Partnership and Licensing Revenue
TypeLicensing Royalties
Description

The company holds worldwide exclusive rights to the AAVLP technology platform and may generate revenue through licensing agreements, co-development partnerships, and strategic collaborations with larger pharmaceutical companies for specific vaccine indications.

2apharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

2A Pharma is a clinical-stage biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform technology. The company's pipeline includes 2AP01, a broad-coverage prophylactic HPV vaccine in Phase 1 clinical trials, and 2AP07, a therapeutic vaccine targeting EpCAM+ cancers (head and neck, breast, colon, pancreatic, prostate). The platform enables vaccine design without viral genomic material, allowing safer immunogenic vaccines with broader coverage than approved alternatives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 clinical trial of AAVLP-HPV (2AP01) completed in 2020, demonstrating safety and immunological effects in healthy adult volunteers
+2 more records
Product overview1 text field

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its patented AAVLP (adeno-associated virus-like particle) platform technology. The core platform enables vaccine development without viral genomic material, featuring two immunogenic positions for broad, cross-protective immune responses. Current portfolio includes two vaccine candidates: 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine currently in Phase 1 clinical trials, and 2AP07 (AAVLP-EpCAM+), a therapeutic vaccine for EpCAM+ cancers in pre-clinical development. The platform technology can be adapted to target infectious diseases, immune-oncology, and autoimmune conditions.

Product and service2 records
12AP01 (AAVLP-HPV)
CategoryVaccine candidate
Description

Prophylactic HPV vaccine candidate using the AAVLP platform technology, targeting cervical, skin, oropharyngeal and other HPV-related cancers including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in immunocompromised patients. It is the world's only L2-based HPV vaccine in clinical testing, designed to provide broader cross-protective coverage against both alpha-HPV and beta-HPV types than currently approved vaccines.

22AP07 (AAVLP-EpCAM+)
CategoryVaccine candidate
Description

Therapeutic vaccine candidate targeting EpCAM+ cancers including head and neck cancer, breast cancer, colon cancer, pancreatic cancer, and prostate cancer. Developed using phage display and next-generation sequencing to identify EpCAM mimotope epitopes incorporated into the AAVLP platform.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Medigene AG
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

2A Pharma in-licensed the AAVLP technology from Medigene AG in 2016. The technology was originally discovered and developed at Medigene AG by John Nieland, Markus Hörer, and Hildegard Büning. Medigene is a biotechnology company developing innovative, complementary treatment platforms to target various types and stages of cancer, focusing on personalised T cell-based immunotherapies. 2A Pharma holds worldwide exclusive rights to develop the AAVLP technology.

2apharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

DTI (Danish Technology Institute) is a leading research and technology company that converts knowledge into value. DTI is screening several large peptide libraries to identify EpCAM mimotopes to be transferred into the AAVLP platform as part of the 2AP07 therapeutic head and neck cancer vaccine project.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

DNASense makes DNA/RNA sequencing and bioinformatics accessible to life science researchers in industry and academia by converting complex data into meaningful and applicable knowledge. DNASense is performing next generation sequencing (NGS) and phage-display customized bioinformatic tools in regard to the EpCAM mimotopes for the 2AP07 project.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Johns Hopkins University is collaborating with 2A Pharma to bring the AAVLP-HPV vaccine to market. The university is analyzing human blood samples from Phase 1 clinical trial volunteers. Johns Hopkins aims to improve the health of the community and the world by setting the standard of excellence in medical education, research, and clinical care.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aalborg University has a strong collaboration with public and private sectors offering degree programmes with a real-world approach. 2A Pharma is in a research collaboration with AAU, and 2A Pharma Co-Founder Dr. John Nieland is professor at the Health Science and Technology department of the Faculty of Medicine at Aalborg University.

6Galveston National Laboratory (GNL), Texas
Strategic tierMinorTypeStrategic or Co-development Partner
Description

The Galveston National Laboratory is a sophisticated high containment research facility serving as a critically important resource in the global fight against infectious diseases, known for expertise with pathogens including Ebola and COVID-19. 2A Pharma is collaborating with GNL on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.

2apharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Stony Brook University is engaged in a research collaboration with 2A Pharma on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

mRNA vaccine platform company with active HPV and oncology vaccine programs. Not a direct VLP peer but a relevant broad incumbent shaping the competitive landscape for next-generation HPV and cancer vaccines.

2Hookipa Pharma
TypeDirect peer
Description

Clinical-stage biotech developing VLP-based arenavirus and cytomegalovirus vaccine platforms for infectious disease and cancer. Closely analogous to 2A Pharma's AAVLP VLP approach and target disease areas.

TypeEmerging player
Description

Clinical-stage US biotech developing VLP-based vaccines for infectious disease (including HPV-related targets) and immuno-oncology. Comparable in stage, technology approach and indication overlap.

TypeBroad incumbent
Description

Large pharma incumbent commercializing Gardasil/Gardasil-9, the dominant prophylactic HPV vaccines worldwide. Defines the standard of care that 2A Pharma's 2AP01 must beat on coverage or cost to gain meaningful share.

TypeDirect peer
Description

Biotech developing enveloped VLP (eVLP) and other VLP-based vaccines targeting infectious disease and oncology, including HPV-related and cancer immunotherapy indications. Direct platform analogue to 2A Pharma's AAVLP VLP technology with comparable stage and indication overlap.

6Valneva
TypeRegional player
Description

European-listed specialty vaccine company developing prophylactic vaccines for infectious diseases, headquartered in France/Austria with US operations. Comparable European clinical-stage vaccine developer with analogous infectious-disease focus and platform-based approach.

TypeEmerging player
Description

Clinical-stage biotech developing immunology-based therapeutics for cancer and infectious disease, including vaccine-like approaches. Comparable in stage, indication overlap (HPV-related cancers) and therapeutic vaccine positioning.

TypeDirect peer
Description

European-listed vaccine biotech developing infectious disease and oncology vaccines using VLP and other platforms; headquartered in Denmark — same geography as 2A Pharma's Danish operating entity. Closely comparable in stage, business model and infectious-disease focus.

TypeDirect peer
Description

Clinical-stage and commercial biotech developing vaccines using a recombinant nanoparticle/VLP platform (Matrix-M adjuvant and rNV-based VLPs). Most comparable to 2A Pharma's AAVLP VLP platform in terms of technology category, scalable manufacturing approach and target indications including infectious disease and oncology vaccines.

TypeEmerging player
Description

Clinical-stage immuno-oncology biotech developing therapeutic cancer vaccines including oncolytic virus and B-cell immunotherapy approaches. Comparable therapeutic vaccine positioning for solid tumors overlapping 2A Pharma's 2AP07 program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

2A Pharma

Biopharmaceutical Vaccines2apharma.com

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing prophylactic and therapeutic vaccines based on its proprietary AAVLP virus-like particle platform, targeting HPV-related cancers, EpCAM+ cancers, and selected infectious and autoimmune diseases.

What 2A Pharma does

2A Pharma AB is a clinical-stage Swedish/Danish biopharmaceutical company founded on December 12, 2016, developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform. The company operates from Malmö, Sweden (parent 2A Pharma AB, registration 559090-2788) and Aalborg, Denmark (operating entity 2A Pharma ApS, CVR 3939 1597) with 1-10 employees, and holds worldwide exclusive rights to the AAVLP technology in-licensed from Medigene AG in 2016. The AAVLP platform uses non-infectious protein scaffolds derived from AAV2 that mimic virus structure without containing viral genomic material, with two immunogenic capsid positions (453 and 587) enabling monovalent and bivalent vaccine design, B-cell receptor cross-linking, conversion of low-immunogenic peptides into immunogenic antigens, and pre-existing Th-cell immune response boosting from population-wide AAV2 seropositivity.

The company's lead candidate is 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine that completed a UK MHRA-approved Phase 1 clinical trial in 2020 and is positioned as the only L2-based HPV vaccine in clinical testing, claiming broader coverage than approved vaccines across alpha and beta HPV types. Its second disclosed asset, 2AP07 (AAVLP-EpCAM+), is a pre-clinical therapeutic vaccine for EpCAM+ cancers including head and neck, breast, colon, pancreatic and prostate cancers, developed in partnership with Danish Technological Institute and DNASense and supported by a EUR 653,000 Eurostars grant. The company also references pan-coronavirus and pan-Ebola vaccine collaborations with the Galveston National Laboratory and Stony Brook University, and exploratory autoimmune-disease work (vitiligo).

2A Pharma is pre-revenue and is monetizing the platform through future licensing, co-development, and outright commercialization pathways rather than current product sales. Revenue is expected upon regulatory approval and commercialization, with the option of licensing or partnership upfront payments in the interim. The company has raised cumulative seed funding of approximately EUR 7.9m from family offices (SEK 27m in 2016, USD 3m in 2018, plus additional capital through 2021) and is currently seeking Series A investment of EUR 15-20m to fund Phase 2 studies and IND progression, with plans for a Series B or IPO targeted for 2024. Customer-facing end markets in scope span patients at risk of HPV-related cancers (target market approximately USD 5.6 billion by 2023), EpCAM+ cancer patients (head and neck cancer market ~USD 1.3 billion, breast cancer drugs market projected to grow from USD 15.4 billion in 2020 to USD 31.1 billion in 2028), and autoimmune disease populations.

2A Pharma firmographics

Firmographics
Name
2A Pharma
Legal name
2A Pharma ApS
Website
https://2apharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing prophylactic and therapeutic vaccines based on its proprietary AAVLP virus-like particle platform, targeting HPV-related cancers, EpCAM+ cancers, and selected infectious and autoimmune diseases.
Ownership category
akta.pro rank

2A Pharma industry classification

Industry
Product category
Biopharmaceutical Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Vaccine development
  • Biopharmaceutical research
  • HPV cancer vaccines
  • Virus-like particles
  • Immunotherapy platform

Where 2A Pharma is headquartered

Location

Headquarters

HQ city
Malmö
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

2A Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Vaccine Development and Commercialization: Pre-revenue clinical-stage company developing prophylactic and therapeutic vaccines. Currently in Phase 1 trials for HPV vaccine (2AP01). Seeking Series A investment of EUR 15-20m for Phase 2 studies and IND-ready progression. Revenue expected upon regulatory approval and commercialization of vaccine candidates.
  2. Partnership and Licensing Revenue: The company holds worldwide exclusive rights to the AAVLP technology platform and may generate revenue through licensing agreements, co-development partnerships, and strategic collaborations with larger pharmaceutical companies for specific vaccine indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

2A Pharma product offering

Product offering

Core offering

2A Pharma is a clinical-stage biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform technology. The company's pipeline includes 2AP01, a broad-coverage prophylactic HPV vaccine in Phase 1 clinical trials, and 2AP07, a therapeutic vaccine targeting EpCAM+ cancers (head and neck, breast, colon, pancreatic, prostate). The platform enables vaccine design without viral genomic material, allowing safer immunogenic vaccines with broader coverage than approved alternatives.

Product overview

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its patented AAVLP (adeno-associated virus-like particle) platform technology. The core platform enables vaccine development without viral genomic material, featuring two immunogenic positions for broad, cross-protective immune responses. Current portfolio includes two vaccine candidates: 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine currently in Phase 1 clinical trials, and 2AP07 (AAVLP-EpCAM+), a therapeutic vaccine for EpCAM+ cancers in pre-clinical development. The platform technology can be adapted to target infectious diseases, immune-oncology, and autoimmune conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • 2AP01 (AAVLP-HPV) Prophylactic HPV vaccine candidate using the AAVLP platform technology, targeting cervical, skin, oropharyngeal and other HPV-related cancers including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in immunocompromised patients. It is the world's only L2-based HPV vaccine in clinical testing, designed to provide broader cross-protective coverage against both alpha-HPV and beta-HPV types than currently approved vaccines.
  • 2AP07 (AAVLP-EpCAM+) Therapeutic vaccine candidate targeting EpCAM+ cancers including head and neck cancer, breast cancer, colon cancer, pancreatic cancer, and prostate cancer. Developed using phage display and next-generation sequencing to identify EpCAM mimotope epitopes incorporated into the AAVLP platform.

Quantifiable outcome

  • Phase 1 clinical trial of AAVLP-HPV (2AP01) completed in 2020, demonstrating safety and immunological effects in healthy adult volunteers
  • +2 more outcomes

Companies that use 2A Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

2A Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

2A Pharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Medigene AGcoreTechnology or Integration · 1 January 20162A Pharma in-licensed the AAVLP technology from Medigene AG in 2016. The technology was originally discovered and developed at Medigene AG by John Nieland, Markus Hörer, and Hildegard Büning. Medigene is a biotechnology company developing innovative, complementary treatment platforms to target various types and stages of cancer, focusing on personalised T cell-based immunotherapies. 2A Pharma holds worldwide exclusive rights to develop the AAVLP technology.
  • Danish Technological Institute (DTI)coreStrategic or Co-development Partner · 1 January 2016DTI (Danish Technology Institute) is a leading research and technology company that converts knowledge into value. DTI is screening several large peptide libraries to identify EpCAM mimotopes to be transferred into the AAVLP platform as part of the 2AP07 therapeutic head and neck cancer vaccine project.
  • DNASensecoreTechnology or Integration · 1 January 2016DNASense makes DNA/RNA sequencing and bioinformatics accessible to life science researchers in industry and academia by converting complex data into meaningful and applicable knowledge. DNASense is performing next generation sequencing (NGS) and phage-display customized bioinformatic tools in regard to the EpCAM mimotopes for the 2AP07 project.
  • Johns Hopkins UniversitycoreStrategic or Co-development PartnerJohns Hopkins University is collaborating with 2A Pharma to bring the AAVLP-HPV vaccine to market. The university is analyzing human blood samples from Phase 1 clinical trial volunteers. Johns Hopkins aims to improve the health of the community and the world by setting the standard of excellence in medical education, research, and clinical care.
  • Aalborg University (AAU)coreStrategic or Co-development PartnerAalborg University has a strong collaboration with public and private sectors offering degree programmes with a real-world approach. 2A Pharma is in a research collaboration with AAU, and 2A Pharma Co-Founder Dr. John Nieland is professor at the Health Science and Technology department of the Faculty of Medicine at Aalborg University.
  • Galveston National Laboratory (GNL), TexasminorStrategic or Co-development PartnerThe Galveston National Laboratory is a sophisticated high containment research facility serving as a critically important resource in the global fight against infectious diseases, known for expertise with pathogens including Ebola and COVID-19. 2A Pharma is collaborating with GNL on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.
  • Stony Brook UniversityminorStrategic or Co-development PartnerStony Brook University is engaged in a research collaboration with 2A Pharma on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

2A Pharma competitors and assessment

Company assessment

Broad incumbents

  • Moderna: mRNA vaccine platform company with active HPV and oncology vaccine programs. Not a direct VLP peer but a relevant broad incumbent shaping the competitive landscape for next-generation HPV and cancer vaccines.
  • Merck & Co. (HPV / Gardasil franchise): Large pharma incumbent commercializing Gardasil/Gardasil-9, the dominant prophylactic HPV vaccines worldwide. Defines the standard of care that 2A Pharma's 2AP01 must beat on coverage or cost to gain meaningful share.

Direct peers

  • Hookipa Pharma: Clinical-stage biotech developing VLP-based arenavirus and cytomegalovirus vaccine platforms for infectious disease and cancer. Closely analogous to 2A Pharma's AAVLP VLP approach and target disease areas.
  • VBI Vaccines: Biotech developing enveloped VLP (eVLP) and other VLP-based vaccines targeting infectious disease and oncology, including HPV-related and cancer immunotherapy indications. Direct platform analogue to 2A Pharma's AAVLP VLP technology with comparable stage and indication overlap.
  • Bavarian Nordic: European-listed vaccine biotech developing infectious disease and oncology vaccines using VLP and other platforms; headquartered in Denmark — same geography as 2A Pharma's Danish operating entity. Closely comparable in stage, business model and infectious-disease focus.
  • Novavax: Clinical-stage and commercial biotech developing vaccines using a recombinant nanoparticle/VLP platform (Matrix-M adjuvant and rNV-based VLPs). Most comparable to 2A Pharma's AAVLP VLP platform in terms of technology category, scalable manufacturing approach and target indications including infectious disease and oncology vaccines.

Emerging players

  • GeoVax Labs: Clinical-stage US biotech developing VLP-based vaccines for infectious disease (including HPV-related targets) and immuno-oncology. Comparable in stage, technology approach and indication overlap.
  • Cue Biopharma: Clinical-stage biotech developing immunology-based therapeutics for cancer and infectious disease, including vaccine-like approaches. Comparable in stage, indication overlap (HPV-related cancers) and therapeutic vaccine positioning.
  • Imugene: Clinical-stage immuno-oncology biotech developing therapeutic cancer vaccines including oncolytic virus and B-cell immunotherapy approaches. Comparable therapeutic vaccine positioning for solid tumors overlapping 2A Pharma's 2AP07 program.

Regional players

  • Valneva: European-listed specialty vaccine company developing prophylactic vaccines for infectious diseases, headquartered in France/Austria with US operations. Comparable European clinical-stage vaccine developer with analogous infectious-disease focus and platform-based approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

2A Pharma social profiles

Digital presence

2A Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

2A Pharma leadership team

Management profile

Number of profiles

Profiles1 record

2A Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

2A Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 2A Pharma

What does 2A Pharma do?

2A Pharma is a clinical-stage biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform technology. The company's pipeline includes 2AP01, a broad-coverage prophylactic HPV vaccine in Phase 1 clinical trials, and 2AP07, a therapeutic vaccine targeting EpCAM+ cancers (head and neck, breast, colon, pancreatic, prostate). The platform enables vaccine design without viral genomic material, allowing safer immunogenic vaccines with broader coverage than approved alternatives.

Is 2A Pharma a public or private company?

2A Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 2A Pharma founded?

2A Pharma was founded in 2016. It employs 1 to 10 people.

Where is 2A Pharma based?

2A Pharma is headquartered in Malmö, Sweden, in the Europe region.

How does 2A Pharma make money?

Two revenue lines are on record. Vaccine Development and Commercialization is the primary driver. The others are partnership and Licensing Revenue.

Who are 2A Pharma's main competitors?

Broad incumbents on record are Moderna and Merck & Co. (HPV / Gardasil franchise). Direct peers are Hookipa Pharma, VBI Vaccines, Bavarian Nordic and Novavax. Emerging players are GeoVax Labs, Cue Biopharma and Imugene. Valneva is listed as a regional player.

Does 2A Pharma have an API?

No public API is recorded for 2A Pharma.

What industry is 2A Pharma in?

2A Pharma's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals